Related Experiment Videos
VEGF-VEGF receptor complexes as markers of tumor vascular endothelium
1The Hope Heart Institute, Department of Vascular Biology, 1124 Columbia St., Seattle, WA 98104-2046, USA.
Abstract:
Vascular endothelial growth factor (VEGF) is a primary stimulant of the vascularization of solid tumors and has therefore been the focus of intense research aimed at blocking its activity in solid tumors. VEGF production by tumor cells is induced by oncogenic gene mutations and hypoxic conditions inside the tumor mass. VEGF receptor expression on endothelial cells lining blood vessels in the tumor is also induced by hypoxia and the increased local concentration of VEGF. Therefore in the tumor microenvironment there is an upregulation of both VEGF and its receptor leading to a high concentration of occupied receptor on tumor vascular endothelium. The VEGF-VEGF receptor complex (VEGF-VEGFR) presents an attractive target for the specific delivery of drugs or other effectors to tumor endothelium. Herein we review the development of monoclonal antibodies that selectively bind to the VEGF-VEGFR and their use as targeting agents that selectively bind to VEGF activated blood vessels. Additionally, we summarize the properties of 2C3, a novel monoclonal anti-VEGF antibody that blocks VEGF from binding to VEGFR2 but not VEGFR1. 2C3 may be utilized as both an anti-angiogenic agent by inhibiting VEGFR2 activity and potentially as a vascular targeting agent by binding to blood vessels that express the VEGF-VEGFR1 complex.
Insights
Vascular endothelial growth factor (VEGF) drives tumor vascularization. Monoclonal antibodies targeting the VEGF-VEGFR complex offer potential for anti-cancer drug delivery and inhibiting tumor growth.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Vascular endothelial growth factor (VEGF) promotes solid tumor vascularization, driven by oncogenic mutations and tumor hypoxia.
- Hypoxia and elevated VEGF upregulate VEGF receptors on tumor endothelial cells, creating a targetable VEGF-VEGF receptor (VEGF-VEGFR) complex.
- The VEGF-VEGFR complex on tumor vasculature is a key target for anti-cancer therapies and drug delivery.
Purpose of the Study:
- To review the development of monoclonal antibodies targeting the VEGF-VEGFR complex for selective drug delivery to tumor endothelium.
- To summarize the properties of 2C3, a novel monoclonal anti-VEGF antibody, and its potential therapeutic applications.
Main Methods:
- Review of literature on monoclonal antibodies targeting VEGF and its receptors.
- Characterization of the novel monoclonal antibody 2C3, focusing on its binding specificities and functional effects.
Main Results:
- Monoclonal antibodies targeting VEGF-VEGFR complexes can selectively bind to VEGF-activated tumor blood vessels.
- The antibody 2C3 selectively blocks VEGF binding to VEGFR2, inhibiting VEGFR2 activity and acting as an anti-angiogenic agent.
- 2C3 also shows potential as a vascular targeting agent by binding to blood vessels expressing the VEGF-VEGFR1 complex.
Conclusions:
- Targeting the VEGF-VEGFR complex with monoclonal antibodies is a promising strategy for cancer therapy.
- The antibody 2C3 offers dual potential as an anti-angiogenic and vascular targeting agent for solid tumors.
- Further research into VEGF-VEGFR targeting antibodies like 2C3 could lead to novel therapeutic approaches in oncology.